This study found that regional- and distant-stage prostate cancer incidence continues to increase in US men aged ≥50 years.
The FDA approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
A recent examination of older adults with cancer found accelerated losses in differing sarcopenia measures existed before and after a cancer diagnosis.
The FDA approved rucaparib for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
The chairman of the Glickman Urological & Kidney Institute at the Cleveland Clinic provides commentary and an adjacent perspective to the Duke Cancer Institute report.
Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute’s Initial Experience
Experts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.
A recent study found that the proportion of men with high-risk prostate-specific antigen levels at diagnosis was decreased in association with Medicaid expansion states.
Olaparib was found to be associated with longer progression-free survival and improved measures of response and patient-reported end points than either enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer.
In a webinar, a multidisciplinary team from Duke Cancer Center came together to discuss the differences in treating patients with genitourinary cancer as a result of the COVID-19 pandemic.
A recent study led by led by King's College London and Public Health England examined 1.4 million patients of cancer via the National Cancer Registry and found that early GP referrals led to longer survival rates for patients.